Johnson Investment Counsel Inc Amgen Inc Transaction History

Johnson Investment Counsel Inc

$10.1 Billion
Q3 2024

A detailed history of Johnson Investment Counsel Inc transactions in Amgen Inc stock. As of the latest transaction made, Johnson Investment Counsel Inc holds 25,710 shares of AMGN stock, worth $6.77 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

25,710

Previous 26,682 3.64%

Holding current value

$6.77 Million

Previous $8.34 Million 0.62%

% of portfolio

0.08%

Previous 0.09%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	SELL	$309.38 - $337.38 $300,717 - $327,933	-972 Reduced 3.64%	25,710 $8.28 Million
Q2 2024 Aug 08, 2024	SELL	$262.75 - $319.31 $82,240 - $99,944	-313 Reduced 1.16%	26,682 $8.34 Million
Q1 2024 May 09, 2024	SELL	$268.87 - $324.56 $309,200 - $373,244	-1,150 Reduced 4.09%	26,995 $7.68 Million
Q4 2023 Feb 07, 2024	BUY	$255.7 - $288.46 $119,923 - $135,287	469 Added 1.69%	28,145 $8.11 Million
Q3 2023 Nov 13, 2023	BUY	$218.65 - $271.46 $325,569 - $404,203	1,489 Added 5.69%	27,676 $7.44 Million
Q2 2023 Aug 10, 2023	SELL	$214.27 - $253.37 $234,411 - $277,186	-1,094 Reduced 4.01%	26,187 $5.81 Million
Q1 2023 May 15, 2023	BUY	$225.79 - $275.2 $276,592 - $337,120	1,225 Added 4.7%	27,281 $6.6 Million
Q4 2022 Feb 14, 2023	BUY	$229.03 - $291.01 $114,056 - $144,922	498 Added 1.95%	26,056 $6.84 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $285,288 - $321,753	-1,271 Reduced 4.74%	25,558 $5.76 Million
Q2 2022 Aug 15, 2022	SELL	$230.71 - $256.74 $87,439 - $97,304	-379 Reduced 1.39%	26,829 $6.53 Million
Q1 2022 May 11, 2022	SELL	$219.27 - $242.57 $92,093 - $101,879	-420 Reduced 1.52%	27,208 $6.58 Million
Q4 2021 Feb 15, 2022	SELL	$198.88 - $227.6 $36,792 - $42,106	-185 Reduced 0.67%	27,628 $6.22 Million
Q3 2021 Nov 12, 2021	SELL	$212.27 - $248.7 $182,552 - $213,882	-860 Reduced 3.0%	27,813 $5.91 Million
Q2 2021 Aug 13, 2021	SELL	$233.58 - $259.14 $283,098 - $314,077	-1,212 Reduced 4.06%	28,673 $6.99 Million
Q1 2021 May 14, 2021	SELL	$221.91 - $258.6 $182,853 - $213,086	-824 Reduced 2.68%	29,885 $7.44 Million
Q4 2020 Feb 12, 2021	BUY	$216.38 - $257.67 $49,334 - $58,748	228 Added 0.75%	30,709 $7.06 Million
Q3 2020 Nov 16, 2020	SELL	$234.65 - $260.95 $3,285 - $3,653	-14 Reduced 0.05%	30,481 $7.75 Million
Q2 2020 Aug 13, 2020	SELL	$197.81 - $242.74 $267,439 - $328,184	-1,352 Reduced 4.25%	30,495 $7.19 Million
Q1 2020 May 20, 2020	SELL	$182.24 - $241.7 $341,153 - $452,462	-1,872 Reduced 5.55%	31,847 $6.46 Million
Q4 2019 Feb 13, 2020	BUY	$189.21 - $243.2 $451,833 - $580,761	2,388 Added 7.62%	33,719 $8.13 Million
Q3 2019 Nov 14, 2019	BUY	$174.11 - $208.62 $1.35 Million - $1.62 Million	7,756 Added 32.9%	31,331 $6.06 Million
Q2 2019 Aug 14, 2019	SELL	$166.7 - $195.41 $507,434 - $594,828	-3,044 Reduced 11.44%	23,575 $4.34 Million
Q1 2019 May 13, 2019	BUY	$180.87 - $203.88 $87,721 - $98,881	485 Added 1.86%	26,619 $5.06 Million
Q4 2018 Feb 13, 2019	BUY	$178.4 - $208.25 $318,265 - $371,518	1,784 Added 7.33%	26,134 $5.09 Million
Q3 2018 Nov 14, 2018	BUY	$185.29 - $208.89 $37,058 - $41,778	200 Added 0.83%	24,350 $5.05 Million
Q2 2018 Aug 14, 2018	BUY	$166.05 - $186.51 $135,828 - $152,565	818 Added 3.51%	24,150 $4.46 Million
Q1 2018 May 15, 2018	SELL	$169.43 - $198.0 $395,788 - $462,528	-2,336 Reduced 9.1%	23,332 $3.98 Million
Q4 2017 Feb 14, 2018	SELL	$168.79 - $188.59 $83,044 - $92,786	-492 Reduced 1.88%	25,668 $4.46 Million
Q3 2017 Nov 14, 2017	BUY	$167.29 - $191.0 $4.38 Million - $5 Million	26,160	26,160 $4.88 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Johnson Investment Counsel Inc, based on Form 13F filings with the SEC.

News

Stay updated on Johnson Investment Counsel Inc with notifications on news.

Account

Johnson Investment Counsel Inc Amgen Inc Transaction History